News

You heard it here first.

 
 
 

Our news

Bringing you the latest!

All news

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Corporate - Investors

17 December 2020

MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations

Investors

9 December 2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

Corporate

12 November 2020

 
 

Press

Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86

Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94

Investors

Investors website

Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure

medincell@newcap.eu
+33 (0)1 44 71 94 94

CONTACT

  • This field is for validation purposes and should be left unchanged.